The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Synthesis and Biological Activity of Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 2-Aryl-Substituted Benzimidazoles
Open accessAbstract
The development of new nonnucleoside inhibitors of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase (RT) active against the drug-induced mutations in RT continues to be a very important goal of AIDS research. We used a known inhibitor of HIV-1 RT, 1-(2,6-difluorophenyl)-1H,3H-thiazolo[3,4-alpha]benzimidazole (TZB), as the lead structure for drug design with the objective of making more potent inhibitors against both wild-type (WT) and variant RTs. A series of structurally related 1,2-substituted benzimidazoles was synthesized and evaluated for their ability to inhibit in vitro polymerization by HIV-1 WT RT. A structure-activity study was carried out for the series of compounds to determine the optimum groups for substitution of the benzimidazole ring at the N1 and C2 positions. The best inhibitor, 1-(2,6-difluorobenzyl)-2-(2,6-difluorophenyl)-4-methylbenzimida zole (35), has an IC50 = 200 nM against HIV-1 WT RT in an in vitro enzyme assay. Cytoprotection assays utilizing HIV-infected MT-4 cells revealed that 35 had strong antiviral activity (EC50 = 440 nM) against wild-type virus while retaining broad activity against many clinically observed HIV-1 strains resistant to nonnucleoside inhibitors. Overall, the activity of 35 against wild-type and resistant strains with amino acid substitution in RT is 4-fold or greater than that of TZB and is comparable to that of other nonnucleoside inhibitors currently undergoing clinical trials, most of which do not have the capacity to inhibit the variant forms of the enzyme.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weislow, O. S., Kiser, R., Fine, D. L., Bader, J., Shoemaker, R. H., & Boyd, M. R. (1989) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.577 · Cited by 685
Tantillo, C., Ding, J., Jacobo-Molina, A., Nanni, R. G., Boyer, P. L., Hughes, S. H., Pauwels, R., Andries, K., Janssen, P. A. J., & Arnold, E. (1994) · Journal of Molecular Biology · doi:10.1006/jmbi.1994.1665 · Cited by 518
Self-citationVaishnav, Y. N., & Wong-Staal, F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.003045 · Cited by 325
Hizi, A., McGill, C., & Hughes, S. H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.4.1218 · Cited by 230
Self-citationHIV resistance to reverse transcriptase inhibitors
De Clercq, E. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90001-9 · Cited by 225
Pauwels, R., Andries, K., Debyser, Z., Van Daele, P., Schols, D., Stoffels, P., De Vreese, K., Woestenborghs, R., Vandamme, A. M., & Janssen, C. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1711 · Cited by 191
De Clercq, E. (1993) · Medicinal Research Reviews · doi:10.1002/med.2610130303 · Cited by 166
Review of HIV-1 reverse transcriptase three-dimensional structure: Implications for drug design
Nanni, R. G., Ding, J., Jacobo‐Molina, A., Hughes, S. H., & Arnold, E. (1993) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171659 · Cited by 137
Self-citationBoyer, P. L., Currens, M. J., McMahon, J. B., Boyd, M. R., & Hughes, S. H. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.2412-2420.1993 · Cited by 122
Self-citationBuckheit, R. W., Hollingshead, M. G., Decker, J. M., White, E. L., McMahon, J. B., Allen, L. B., Ross, L. J., Decker, W. D., Westbrook, L., Shannon, W. M., et al. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90031-d · Cited by 87
Buckheit, R. W., III, Fliakas-Boltz, V., DECKER, W., ROBERSON, J., Stup, T. L., Pyle, C., White, E. A., McMahon, J. B., Currens, M. J., & Boyd, M. R. (1995) · Antiviral Research · doi:10.1016/0166-3542(94)00069-k · Cited by 63
Competitive inhibitors of human immunodeficiency virus reverse transcriptase
Schinazi, R. F. (1993) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171660 · Cited by 48
Non-nucleoside inhibitors of HIV-1 reverse transcriptase
Young, S. D. (1993) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171661 · Cited by 44
Cited by
Lentivirus-mediated gene transfer in primary T cells is enhanced by a central DNA flap
Dardalhon, V, Herpers, B., Noraz, N., Pflumio, F., Guetard, D., Leveau, C., Dubart-Kupperschmitt, A., Charneau, P., & Taylor, N. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301378 · Cited by 90
Metadata
- Authors
- Roth, T., Morningstar, M. L., Boyer, P. L., Hughes, S. H., Buckheit, & Michejda, C. J.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1997-12-01
- Volume
- 40
- Issue
- 26
- Pages
- 4199-4207
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2135486341
- Cited by
- 370
- References
- 13
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.